"SUBJECT_ID"	"GenSig:sen"	"GenSig:res"	"Feature.sensitive"	"Feature.resistant"	"dGensig"	"mySlope"	"TEST_SET"	"PatientID"	"BGUSCT"	"Erstatus"	"Prstatus"	"HER2status"	"TreatmentArm"	"DrugTreatment"	"Age"	"ECOG"	"Inflammatory"	"Menopausalstatus"	"pCR_patient"	"pCR_Breast"	"label"	"senlabel"
"GSM1232994"	0.600290502302157	0.0626715156268134	8747	16760	0.38591179462141	0.975611003176438	1	"patid: 191"	"bgus.ct: 30.75"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 55"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: pre"	"pcr: RD"	0	"res"	"other"
"GSM1232996"	0.252146757479256	0.271208013936325	8747	16760	-0.00890916419687721	0.975611003176438	1	"patid: 131"	"bgus.ct: 30.09"	"er: ER+"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 73"	"ecog: 1"	"inflammatory.brca: no"	"menopausal.status: post"	"pcr: RD"	0	"res"	"other"
"GSM1232997"	0.682270706153404	0.74715410673708	8747	16760	-0.0333991246570913	0.975611003176438	1	"patid: 91"	"bgus.ct: 31.9"	"er: ER+"	"pr: PR+"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 49"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: pre"	"pcr: RD"	0	"res"	"other"
"GSM1232998"	0.091572361338925	0.258791061215692	8747	16760	-0.115174286746641	0.975611003176438	1	"patid: 151"	"bgus.ct: 30.98"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 47"	"ecog: 1"	"inflammatory.brca: no"	"menopausal.status: pre"	"pcr: RD"	0	"res"	"other"
"GSM1232999"	0.422953122406387	0.11704596948844	8747	16760	0.221005975501714	0.975611003176438	1	"patid: 71"	"bgus.ct: 31.62"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 60"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: post"	"pcr: RD"	0	"res"	"other"
"GSM1233000"	1	0.263655346442742	8747	16760	0.53166456446777	0.975611003176438	1	"patid: 111"	"bgus.ct: 29.22"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 53"	"ecog: 0"	"inflammatory.brca: yes"	"menopausal.status: post"	"pcr: RD"	0	"res"	"other"
"GSM1233001"	0.846999153148677	0.41829644450979	8747	16760	0.314159750457069	0.975611003176438	1	"patid: 41"	"bgus.ct: 29.34"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 44"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: post"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233004"	0.533235757388826	0.868476469351405	8747	16760	-0.224797939252215	0.975611003176438	1	"patid: 81"	"bgus.ct: 31.96"	"er: ER+"	"pr: PR+"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 67"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: post"	"pcr: RD"	0	"res"	"other"
"GSM1233006"	0.366024148091862	0.143063830017512	8747	16760	0.162088364262103	0.975611003176438	1	"patid: 21"	"bgus.ct: 31.02"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 51"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: post"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233008"	0.443204969676849	0.208476735285701	8747	16760	0.171653546778836	0.975611003176438	1	"patid: 381"	"bgus.ct: 30.27"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 64"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: post"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233009"	0.623491809029593	0.285885174156407	8747	16760	0.246643336859726	0.975611003176438	1	"patid: 321"	"bgus.ct: 30.67"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 50"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: pre"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233011"	0.120797009152049	0.289388473499199	8747	16760	-0.115622741236505	0.975611003176438	1	"patid: 331"	"bgus.ct: 30.94"	"er: ER+"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 59"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: post"	"pcr: RD"	0	"res"	"other"
"GSM1233012"	0.462162069382864	1	8747	16760	-0.367517249131237	0.975611003176438	1	"patid: 301"	"bgus.ct: 31.75"	"er: ER+"	"pr: PR+"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 47"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: pre"	"pcr: RD"	0	"res"	"other"
"GSM1233017"	0.871051818278697	0.0841394749592009	8747	16760	0.564726138232152	0.975611003176438	1	"patid: 221"	"bgus.ct: 29.79"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 60"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: post"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233020"	0.547734634618237	0.438691918642161	8747	16760	0.0857090884410454	0.975611003176438	1	"patid: 261"	"bgus.ct: 29.5"	"er: ER+"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 59"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: post"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233022"	0.880648701736847	0.223485526210406	8747	16760	0.474286674880973	0.975611003176438	1	"patid: 241"	"bgus.ct: 31.02"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 54"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: post"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233023"	0.526340958711301	0.693447834688249	8747	16760	-0.107506358178525	0.975611003176438	1	"patid: 421"	"bgus.ct: 31.45"	"er: ER+"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 51"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: post"	"pcr: RD"	0	"res"	"other"
"GSM1233026"	0.406118947618383	0.149552614932593	8747	16760	0.186256203852662	0.975611003176438	1	"patid: 401"	"bgus.ct: 32.32"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 48"	"ecog: 0"	"inflammatory.brca: yes"	"menopausal.status: pre"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233027"	0.503251179002465	0.049744721266729	8747	16760	0.325479936762373	0.975611003176438	1	"patid: 511"	"bgus.ct: 30.04"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 52"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: pre"	"pcr: RD"	0	"res"	"other"
"GSM1233028"	0.56672707564182	0.378929538831381	8747	16760	0.14103704901742	0.975611003176438	1	"patid: 451"	"bgus.ct: 31.35"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 64"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: post"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233033"	0.325020508508495	0.370079267725544	8747	16760	-0.025791681237602	0.975611003176438	1	"patid: 91"	"bgus.ct: 33.46"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 48"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: post"	"pcr: RD"	0	"res"	"other"
"GSM1233034"	0.564185534895705	0.196777039939065	8747	16760	0.266419379160868	0.975611003176438	1	"patid: 101"	"bgus.ct: 30.27"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 53"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: pre"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233036"	0.495980023807529	0.827361840846659	8747	16760	-0.222753559643121	0.975611003176438	1	"patid: 81"	"bgus.ct: 30.56"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 44"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: pre"	"pcr: RD"	0	"res"	"other"
"GSM1233037"	0.559066064303944	0.649844452543567	8747	16760	-0.0536330312137308	0.975611003176438	1	"patid: 91"	"bgus.ct: 31.75"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 39"	"ecog: 0"	"inflammatory.brca: yes"	"menopausal.status: pre"	"pcr: RD"	0	"res"	"other"
"GSM1233040"	0.61470311779661	0.409099393936417	8747	16760	0.154309069309076	0.975611003176438	1	"patid: 141"	"bgus.ct: 33.63"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 48"	"ecog: 0"	"inflammatory.brca: yes"	"menopausal.status: pre"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233041"	0.346742879217629	0.285366343279765	8747	16760	0.0489138843616648	0.975611003176438	1	"patid: 121"	"bgus.ct: 34.27"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 46"	"ecog: 0"	"inflammatory.brca: yes"	"menopausal.status: pre"	"pcr: RD"	0	"res"	"other"
"GSM1233045"	0.502057555079117	0.129996945805941	8747	16760	0.268583483557366	0.975611003176438	1	"patid: 31"	"bgus.ct: 30.92"	"er: ER+"	"pr: PR+"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 35"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: pre"	"pcr: RD"	0	"res"	"other"
"GSM1233047"	0.245414688167551	0.480312142341722	8747	16760	-0.159750350945525	0.975611003176438	1	"patid: 491"	"bgus.ct: 32.93"	"er: ER+"	"pr: PR+"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 35"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: pre"	"pcr: RD"	0	"res"	"other"
"GSM1233048"	0.68400346115696	0.202060689583478	8747	16760	0.348493133420942	0.975611003176438	1	"patid: 441"	NA	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 47"	"ecog: 0"	"inflammatory.brca: yes"	"menopausal.status: pre"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233050"	0.492041480759937	0.325003483597738	8747	16760	0.125236357000862	0.975611003176438	1	"patid: 421"	"bgus.ct: 33.56"	"er: ER-"	"pr: PR+"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 50"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: pre"	"pcr: RD"	0	"res"	"other"
"GSM1233052"	0.605708865867082	0.248540846211659	8747	16760	0.259993087111874	0.975611003176438	1	"patid: 301"	"bgus.ct: 33.53"	"er: ER-"	"pr: PR+"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 41"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: pre"	"pcr: RD"	0	"res"	"other"
"GSM1233053"	0.566689209427366	0.646819682986966	8747	16760	-0.0460642548340936	0.975611003176438	1	"patid: 31"	"bgus.ct: 31.82"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 54"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: pre"	"pcr: RD"	0	"res"	"other"
"GSM1233055"	0.332340996577919	0.35625326971129	8747	16760	-0.010896780775237	0.975611003176438	1	"patid: 71"	"bgus.ct: 34.81"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 52"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: pre"	"pcr: RD"	0	"res"	"other"
"GSM1233056"	0.245010982738906	0.529375051090068	8747	16760	-0.194301137693103	0.975611003176438	1	"patid: 91"	"bgus.ct: 34.41"	"er: ER+"	"pr: PR+"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 56"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: post"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233058"	0.385241814952911	0.208100177022344	8747	16760	0.130427552607781	0.975611003176438	1	"patid: 801"	"bgus.ct: 32.11"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 45"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: pre"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233059"	0.621345918878831	0.47258145268267	8747	16760	0.114732798612481	0.975611003176438	1	"patid: 861"	"bgus.ct: 32.03"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 57"	"ecog: 0"	"inflammatory.brca: yes"	"menopausal.status: post"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233061"	0.396104481824776	0.740423133431899	8747	16760	-0.233531212299527	0.975611003176438	1	"patid: 661"	"bgus.ct: 32.34"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 45"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: pre"	"pcr: RD"	0	"res"	"other"
"GSM1233063"	0.146393706307738	0.221497359575944	8747	16760	-0.0498910836495249	0.975611003176438	1	"patid: 891"	"bgus.ct: 33.73"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 37"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: pre"	"pcr: RD"	0	"res"	"other"
"GSM1233065"	0.340642333119028	0.339523800902159	8747	16760	0.00672775711734606	0.975611003176438	1	"patid: 631"	"bgus.ct: 30.06"	"er: ER-"	"pr: PR+"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 42"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: pre"	"pcr: RD"	0	"res"	"other"
"GSM1233066"	0.140963219171254	0.409037942800862	8747	16760	-0.184742274156937	0.975611003176438	1	"patid: 551"	"bgus.ct: 32.48"	"er: ER+"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 35"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: pre"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233070"	0.357012912830198	0.104788041419917	8747	16760	0.182367202389479	0.975611003176438	1	"patid: 41"	"bgus.ct: 30.95"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 55"	"ecog: 0"	"inflammatory.brca: yes"	"menopausal.status: post"	"pcr: RD"	0	"res"	"other"
"GSM1233071"	0.74246795044493	0.369637221630124	8747	16760	0.273318167373473	0.975611003176438	1	"patid: 161"	"bgus.ct: 29.49"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 41"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: pre"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233074"	0.389097452530624	0.761154059081576	8747	16760	-0.253023623591397	0.975611003176438	1	"patid: 121"	"bgus.ct: 29.71"	"er: ER+"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 55"	"ecog: 0"	"inflammatory.brca: yes"	"menopausal.status: post"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233076"	0.29584267230205	0.266938108582592	8747	16760	0.0253493420621703	0.975611003176438	1	"patid: 51"	"bgus.ct: 30.42"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 45"	"ecog: 0"	"inflammatory.brca: yes"	"menopausal.status: post"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233077"	0	0.55981487908653	8747	16760	-0.390932338836495	0.975611003176438	1	"patid: 61"	"bgus.ct: 0"	"er: ER+"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 58"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: post"	"pcr: RD"	0	"res"	"other"
"GSM1233080"	0.576930333678822	0.243822359212648	8747	16760	0.242688980286244	0.975611003176438	1	"patid: 61"	"bgus.ct: 33.24"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 58"	"ecog: 0"	"inflammatory.brca: yes"	"menopausal.status: post"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233081"	0.312947645412156	0.751964636702573	8747	16760	-0.301113049885811	0.975611003176438	1	"patid: 141"	"bgus.ct: 32"	"er: ER+"	"pr: PR+"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 46"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: post"	"pcr: RD"	0	"res"	"other"
"GSM1233084"	0.524369561288793	0.414487426140223	8747	16760	0.0858873866654738	0.975611003176438	1	"patid: 81"	"bgus.ct: 33.4"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 36"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: pre"	"pcr: RD"	0	"res"	"other"
"GSM1233087"	0.298512414251085	0.0954840674542494	8747	16760	0.146990818831719	0.975611003176438	1	"patid: 11"	"bgus.ct: 32.98"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 52"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: pre"	"pcr: RD"	0	"res"	"other"
"GSM1233088"	0.549927281138109	0.283035006429035	8747	16760	0.195977549987211	0.975611003176438	1	"patid: 301"	"bgus.ct: 31.52"	"er: ER-"	"pr: PR+"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 41"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: pre"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233089"	0.183468620190182	0.313950144974998	8747	16760	-0.0879155736139776	0.975611003176438	1	"patid: 351"	"bgus.ct: 30.93"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 49"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: post"	"pcr: RD"	0	"res"	"other"
"GSM1233090"	0.507840718938777	0.376852659843841	8747	16760	0.100337619242425	0.975611003176438	1	"patid: 21"	"bgus.ct: 32.69"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 56"	"ecog: 0"	"inflammatory.brca: yes"	"menopausal.status: post"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233092"	0.258804430031325	0	8747	16760	0.185247423702568	0.975611003176438	1	"patid: 221"	"bgus.ct: 30.66"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 56"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: post"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233094"	0.404505729660516	0.0806535554477073	8747	16760	0.233215380413311	0.975611003176438	1	"patid: 141"	"bgus.ct: 31.51"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 60"	"ecog: 0"	"inflammatory.brca: yes"	"menopausal.status: post"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233097"	0.402298137533226	0.18928868662283	8747	16760	0.155772673848488	0.975611003176438	1	"patid: 61"	"bgus.ct: 31.26"	"er: ER-"	"pr: PR+"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 58"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: post"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233099"	0.168958153913953	0.13886646669017	8747	16760	0.0239632917647845	0.975611003176438	1	"patid: 101"	"bgus.ct: 31.83"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 52"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: post"	"pcr: RD"	0	"res"	"other"
"GSM1233100"	0.283998049645889	0.0357177237012244	8747	16760	0.178337995858598	0.975611003176438	1	"patid: 111"	"bgus.ct: 32.87"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 46"	"ecog: 0"	"inflammatory.brca: yes"	"menopausal.status: pre"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233104"	0.740656834162703	0.399392757490204	8747	16760	0.251242789809666	0.975611003176438	1	"patid: 31"	"bgus.ct: 30.83"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 42"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: post"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233106"	0.609194003289415	0.164957894188346	8747	16760	0.320855691261659	0.975611003176438	1	"patid: 101"	"bgus.ct: 34.21"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 26"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: pre"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233111"	0.856537020429383	0.601367719497114	8747	16760	0.193143657748348	0.975611003176438	1	"patid: 21"	"bgus.ct: 31.96"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 76"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: post"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233112"	0.348378524582192	0.603447919670482	8747	16760	-0.172039448111862	0.975611003176438	1	"patid: 51"	"bgus.ct: 33.35"	"er: ER+"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 58"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: post"	"pcr: RD"	0	"res"	"other"
"GSM1233122"	0.291507754089571	0.0407266333521667	8747	16760	0.180215460013438	0.975611003176438	1	"patid: 21"	"bgus.ct: 29.5"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 38"	"ecog: 0"	"inflammatory.brca: yes"	"menopausal.status: pre"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233146"	0.194882445697198	0.0194941379342529	8747	16760	0.125880019322082	0.975611003176438	1	"patid: 161"	"bgus.ct: 26.6425"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 58"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: post"	"pcr: pCR"	1	"sen"	"sen"
